MARKET

PFNX

PFNX

PFENEX
AMEX

Real-time Quotes | Nasdaq Last Sale

12.83
+5.17
+67.49%
After Hours: 12.78 -0.05 -0.39% 17:51 08/11 EDT
OPEN
12.65
PREV CLOSE
7.66
HIGH
13.38
LOW
12.50
VOLUME
12.83M
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
5.26
MARKET CAP
439.97M
P/E (TTM)
-51.9223
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PFNX stock price target is 17.25 with a high estimate of 20.00 and a low estimate of 13.00.

EPS

PFNX News

More
Mid-Afternoon Market Update: Dow Rises 1%; Kforce Shares Climb On Upbeat Q2 Results
Toward the end of trading Tuesday, the Dow traded up 1.06% to 28085.22 while the NASDAQ fell 0.22% to 10,944.77. The S&P also rose, gaining 0.45% to 3,375.46.
Benzinga · 3h ago
Mid-Day Market Update: Gold Plunges Over 4%; Pfenex Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 0.97% to 28061.49 while the NASDAQ fell 0.19% to 10,947. The S&P also rose, gaining 0.35% to 3,372.07.
Benzinga · 6h ago
Mid-Morning Market Update: Markets Mostly Higher; SYSCO Reports Q2 Loss
Following the market opening Tuesday, the Dow traded up 1.06% to 28,085.34 while the NASDAQ fell 0.57% to 10,905.91. The S&P also rose, gaining 0.26% to 3,369.12.
Benzinga · 8h ago
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 10h ago
Pfenex shares are trading higher after the company announced it will be acquired by Ligand for $12 per share in cash.
Benzinga · 11h ago
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
Pre-open movers
Benzinga · 11h ago
7 Stocks To Watch For August 11, 2020
Some of the stocks that may grab investor focus today are:
Benzinga · 14h ago
PFENEX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PFNX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pfenex Inc. (NYSE: PFNX) breached their fiduciary duties or violated the federal securities laws in connection wit
Business Wire · 21h ago

Industry

Biotechnology & Medical Research
-2.36%
Pharmaceuticals & Medical Research
-0.93%

Hot Stocks

Symbol
Price
%Change

About PFNX

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
More

Webull offers kinds of Pfenex Inc stock information, including AMEX:PFNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PFNX stock methods without spending real money on the virtual paper trading platform.